2023
Cangrelor in Patients With Coronary Artery Disease Pretreated With聽Ticagrelor: The Switching Antiplatelet (SWAP)-5 Study.
JACC. Cardiovascular interventions
鈥�Treats Adults
Daniel E Soffer, MD
Cardiologist, Interventional Cardiologist
Daniel E Soffer, MD
(904) 383-1011
Request appointment online
Research at a glance
Top areas of exploration
- Platelet Aggregation Inhibitors , 14 publications
- Clopidogrel , 11 publications
- Ticagrelor , 10 publications
- Platelet Aggregation , 8 publications
Research activity
My publications
Filter publications
37 publications
2022
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy.
European heart journal. Cardiovascular pharmacotherapy
鈥�2022
Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease.
European heart journal. Cardiovascular pharmacotherapy
鈥�2022
Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease.
Thrombosis and haemostasis
鈥�2021
Impact of Timing of Pharmacodynamic Assessment on Platelet Reactivity in Patients Treated With Cangrelor.
JACC. Cardiovascular interventions
鈥�